Literature DB >> 10430296

Radical surgery for gallbladder cancer. Results of the French Surgical Association Survey.

P Cubertafond1, M Mathonnet, A Gainant, B Launois.   

Abstract

BACKGROUND/AIMS: Gallbladder carcinoma is a highly lethal disease. The advantages of radical surgery remain controversial. The authors' objective was to evaluate the effectiveness of an aggressive approach to gallbladder carcinoma on long-term survival.
METHODOLOGY: A questionnaire was sent to 73 institutions in France, Europe, and overseas. Data, from 724 patients treated between 1980 and 1989, were analyzed for patient sex and age, associated hepatobiliary diseases, symptoms and signs, diagnostic tests, operative management, pathology reports and survival. Seventy-eight percent of the patients were women, and 22% were men. Gallstones were present in 86% of the cases. Four percent of the patients had Tis lesions, 11% had T1 to T2 lesions, and 85% had T3 to T4 lesions.
RESULTS: Twenty-three percent of the patients underwent curative operations, and 77% had a palliative treatment (25% of the patients underwent exploratory laparotomy). Exploratory laparotomy was followed by the highest mortality rate (66%), and older patients (>70 years) had a higher operative risk. The overall median survival was 3 months, and long-term survival correlated with cancer stage: Tis >60 months, T1 to T2 >22 months, and T3 to T4 2 to 8 months. Projected five-year survival for cancers limited to the gallbladder and treated by simple cholecystectomy was 93%, 18% and 10% for Tis, T1 and T2 respectively. For T3 to T4, no difference was observed among the different surgical procedures adopted--hepatic resection, trans-tumoral stenting or biliary-enteric anastomosis.
CONCLUSIONS: In conclusion, a simple cholecystectomy is effective only for Tis cancer. An extended cholecystectomy for invasive cancer should be performed, but only if there is limited involvement of the immediately adjacent hepatic parenchyma. There is now a need to evaluate more effective adjuvant therapy in the form of radiotherapy or newer chemotherapeutic agents.

Entities:  

Mesh:

Year:  1999        PMID: 10430296

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

Review 1.  Routine histopathology for carcinoma in cholecystectomy specimens not evidence based: a systematic review.

Authors:  Hilko A Swank; Irene M Mulder; Wim C Hop; Marc J van de Vijver; Johan F Lange; Willem A Bemelman
Journal:  Surg Endosc       Date:  2013-07-23       Impact factor: 4.584

Review 2.  Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it.

Authors:  Ketao Jin; Huanrong Lan; Tieming Zhu; Kuifeng He; Lisong Teng
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

3.  Radical resection for T1b gallbladder cancer: a decision analysis.

Authors:  Michael A Abramson; Pari Pandharipande; Daniel Ruan; Jason S Gold; Edward E Whang
Journal:  HPB (Oxford)       Date:  2009-12       Impact factor: 3.647

4.  Is there any justification for the routine histological examination of straightforward cholecystectomy specimens?

Authors:  B Darmas; S Mahmud; A Abbas; A L Baker
Journal:  Ann R Coll Surg Engl       Date:  2007-04       Impact factor: 1.891

5.  Skp2-RNAi suppresses proliferation and migration of gallbladder carcinoma cells by enhancing p27 expression.

Authors:  Bin Zhang; Lin-Hua Ji; Wei Liu; Gang Zhao; Zhi-Yong Wu
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

6.  Gall bladder cancer--radical surgery, the key role to improve outcome.

Authors:  P Bhuta; M G Brown; J M Alderdice
Journal:  Ulster Med J       Date:  2002-11

Review 7.  A Review of the Etiology and Epidemiology of Gallbladder Cancer: What You Need to Know.

Authors:  Sattam A Halaseh; Shahed Halaseh; Raed Shakman
Journal:  Cureus       Date:  2022-08-22

8.  Extended Resections for Advanced Gallbladder Cancer: Results from a Nationwide Cohort Study.

Authors:  H Kuipers; E A J de Savornin Lohman; M van Dooren; A E Braat; F Daams; R van Dam; J I Erdmann; J Hagendoorn; F J H Hoogwater; B Groot Koerkamp; T M van Gulik; P R de Reuver; M T de Boer
Journal:  Ann Surg Oncol       Date:  2020-07-21       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.